The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40 ...

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the ...

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...